Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Associations of <sup>18</sup>F-RO-948 tau PET with fluid AD biomarkers, Centiloid, and cognition in early AD continuum.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Performance of a fully automated plasma tau phosphorylated at threonine 217 immunoassay to reflect amyloid-beta burden in an unselected cohort representative of clinical practice.

The journal of prevention of Alzheimer's disease·2026
Same author

Physical activity across the life course and neural biomarkers.

Journal of Alzheimer's disease : JAD·2026
Same author

Biomarkers.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Developing Topics.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

High-Density EEG Source Localisation of averaged interictal epileptic Discharges validated by surgical Outcome.

Scientific data·2025

Related Experiment Video

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

Biomarkers.

Imke Kirste1, David Caley2, Clara Quijano Rubio3

  • 1Roche Diagnostics, Durham, NC, USA.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 24, 2025
PubMed
Summary

Clinical trial design can achieve better representation of diverse patient populations, including minorities and those with comorbidities. This approach leads to more accurate diagnostic test results and better post-launch utility for Alzheimer's disease.

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Related Experiment Videos

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Area of Science:

  • Biomarker Development
  • Clinical Trial Design
  • Neurodegenerative Diseases

Background:

  • Healthcare access and diagnostic test availability are unevenly distributed across populations.
  • Current diagnostic test development often lacks representation from minority groups and individuals with comorbidities.
  • Improved clinical trial design is crucial for developing medical tests that benefit a broader patient population.

Purpose of the Study:

  • To develop a novel blood-based biomarker for early Alzheimer's disease progression.
  • To ensure diverse patient enrollment, including racial/ethnic minorities and individuals with comorbidities, in a clinical study.
  • To create diagnostic tests with broader clinical value and real-world applicability.

Main Methods:

  • Implementing mobile units for patient recruitment and utilizing multilingual study materials.
  • Conducting outreach events and selecting study sites based on geographic location and diverse enrollment capabilities.
  • Enrolling 1500 patients in a clinical trial with two arms: cut-off determination and validation.

Main Results:

  • The study achieved significant representation of racial and ethnic minorities and included patients with multiple comorbidities.
  • In the cut-off determination arm (n=600), 64.5% were non-Hispanic Caucasian, 12.5% were African American, and other minorities were included.
  • The patient population reflected diverse comorbidities, including cardiovascular, metabolic, neurological, and oncological conditions.

Conclusions:

  • A well-designed clinical trial can accurately reflect the real-world patient population.
  • This improved representation leads to more accurate diagnostic test results.
  • Enhanced trial design ensures better reflection of post-launch usage and clinical utility.